Phaseline

Companies › Shanghai Jiaolian Drug Research and Development

Shanghai Jiaolian Drug Research and Development: clinical trials, targets and expected readouts

3 active drug programs in 6 registered trials: 5 Phase 2, 1 Phase 1; Neurology, Genitourinary, Immunology, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
B007
Anti-CD20 monoclonal antibody
CD20Phase 2Generalized Myasthenia Gravis; Pemphigus; Primary Membranous NephropathyDec 2026
B013–Phase 2Platinum-resistant Recurrent Ovarian CancerDec 2026
B001–Phase 2Neuromyelitis Optica Spectrum DisordersOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06447597B007Phase 2Generalized Myasthenia GravisNeurologyDec 2026
NCT05668403B007Phase 1Primary Membranous NephropathyGenitourinaryDec 2026
NCT06454357B007Phase 2PemphigusImmunologyDec 2026
NCT06470191B007Phase 2Primary Membranous NephropathyGenitourinaryDec 2026
NCT06434610B013Phase 2Platinum-resistant Recurrent Ovarian CancerOncologyDec 2026
NCT06413654B001Phase 2Neuromyelitis Optica Spectrum DisordersNeurologyOct 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CD20 (1)

Companies with the same targets

AstraZeneca Johnson & Johnson (Janssen) Lyell Immunopharma Zhejiang Teruisi Pharmaceutical AvenCell Therapeutics Adicet Therapeutics Cellectis Biocad Gilead Sciences Shanghai AbelZeta

Companies built like this

Arctic Therapeutics Woolsey Pharmaceuticals Kissei Pharmaceutical Sundance Biosciences Teikoku Pharma USA

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.